Company profile: NGM Bio
1.1 - Company Overview
Company description
- Provider of biotherapeutic drug discovery focused on the gastrointestinal endocrine system, developing: NGM707 (ILT2/ILT4 antagonist), NGM831 (ILT3 antagonist), NGM438 (LAIR1 antagonist) for advanced solid tumors; NGM120 (GFRAL antagonist) for advanced solid tumors and cachexia; NGM621 (anti-Complement C3) for geographic atrophy; aldafermin (FGF19 analog) for NASH F4 and primary sclerosing cholangitis.
Products and services
- NGM621: A clinical-stage anti-Complement C3 therapeutic antibody engineered to target C3 for geographic atrophy
- Completed Phase 2 trial
- Aldafermin: A clinical-stage FGF19 analog crafted for NASH F4 and primary sclerosing cholangitis
- Completed Phase 2 trials
- NGM120: An investigational GFRAL antagonist therapeutic antibody targeting advanced solid tumors and cachexia
- In Phase 2 trial.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to NGM Bio
MetaVia Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage multimodal disease-modifying therapies, including DA-1241, an oral GPR119 agonist in Phase 2a for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and DA-1726, a once-weekly dual oxyntomodulin analog agonist targeting GLP1R and GCGR for obesity, with a Phase 1 clinical trial expected to begin in 2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaVia Therapeutics company profile →
HighTide Therapeutics
HQ: China
Website
- Description: Provider of global clinical-stage biopharmaceutical drug development, centered on HTD1801, a candidate targeting NASH, type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC). Conducts multi-regional clinical trials, including a Phase 2b study for NASH and a Phase 3 study for T2DM.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HighTide Therapeutics company profile →
Aligos Therapeutics
HQ: United States
Website
- Description: Provider of small molecule and oligonucleotide platforms and a pipeline of drug candidates for MASH and viral diseases, including COVID-19 protease inhibitors (partly funded by NIH and NIAID), a capsid assembly modulator (ALG-000184) for chronic hepatitis B, STOPSTM to reduce HBV S-antigen, and next-generation antisense oligonucleotides (e.g., ALG-020572).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aligos Therapeutics company profile →
Embark Biotech
HQ: Denmark
Website
- Description: Provider of biotech research identifying novel cell surface receptors that physiologically regulate fat tissue calorie-burning and glucose and lipid uptake; founded in 2017 and headquartered in Copenhagen, Denmark.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Embark Biotech company profile →
Akero Therapeutics
HQ: United States
Website
- Description: Provider of investigational therapies for metabolic dysfunction-associated steatohepatitis (MASH), including efruxifermin (EFX), which mimics FGF21 to regulate metabolic pathways and cellular processes; clinical trials (SYNCHRONY, SYMMETRY, HARMONY, BALANCED) evaluating EFX; pipeline development for MASH and other serious metabolic diseases; and manufacturing partnerships with Boehringer-Ingelheim and Vetter Pharma.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Akero Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for NGM Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to NGM Bio
2.2 - Growth funds investing in similar companies to NGM Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for NGM Bio
4.2 - Public trading comparable groups for NGM Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →